Nigeria Allocates N73.4bn to Prevent TB Drug Stockouts
The Federal Government has allocated N73.4 billion for the procurement of tuberculosis drugs and commodities to prevent nationwide stockouts, while expanding molecular-grade diagnostic technology to remote communities as global health financing undergoes major realignment.
The World Health Organisation has simultaneously called for increased domestic funding and stronger community engagement to sustain Nigeria’s fight against TB, warning that reliance on external support could jeopardise long-term programme sustainability as international donors recalibrate their funding priorities.
Director of Public Health in the Federal Ministry of Health and Social Welfare, Dr Charles Nzelu, disclosed the funding allocation on Tuesday at a pre-World TB Day briefing in Abuja, stating that the government was taking proactive measures to ensure uninterrupted supply of essential TB medications following last year’s announcement by major global funders of funding withdrawals for AIDS, Tuberculosis and Malaria programmes.
“Following the announcement of funding withdrawal last year by major global funders for AIDS, Tuberculosis and Malaria, which significantly impacted on ATM management across the globe, Nigeria announced the provision of $200 million, state-wide money, to plug the lacuna created by the United States government funding cut,” Nzelu stated.
He explained that the government was already forecasting potential drug shortages based on current projections, noting that some essential medications not covered by Global Fund procurement would require urgent domestic intervention to prevent supply disruptions.
“There were some medications the Global Fund was not procuring for the country. Going by projections, the government is already forecasting that in some months’ time, we will begin to run out of stock of some of these drugs,” he said.
The allocation comes as Nigeria grapples with the highest tuberculosis burden in Africa and ranks sixth globally in TB prevalence, with the disease continuing to claim thousands of lives annually despite available treatment protocols. TB, caused by the bacterium Mycobacterium tuberculosis, primarily affects the lungs but can spread to other organs if left untreated. It remains one of the top infectious disease killers worldwide, particularly affecting low and middle-income countries with weak health systems and high poverty rates.
According to available data, Nigeria records over 500,000 new TB cases each year, driven predominantly by socio-economic factors including poverty, malnutrition, overcrowding, and unemployment. These conditions create environments conducive to TB transmission and complicate treatment adherence, as patients often face financial barriers to accessing healthcare facilities and completing the required six to nine months of antibiotic therapy.
Board Chairman of Stop TB Partnership Nigeria, Dr Queen Ogbuji-Ladipo, emphasized the persistent challenge TB poses to Nigeria’s public health system, stating that “TB remains one of the leading infectious diseases globally,” with Nigeria continuing to bear a disproportionate share of the burden.
The disease’s prevalence correlates strongly with socio-economic deprivation, as noted by health experts who observe that “wherever you see poverty, malnutrition, overcrowding and joblessness, you will see TB.”
Beyond drug procurement, the Federal Government has announced plans to expand the national rollout of TB near-point-of-care technology, specifically the Pluslife Mini Dock diagnostic equipment, to bring molecular-grade testing capabilities to Nigeria’s most geographically isolated communities. This expansion aims to address diagnostic gaps that have historically prevented early detection and treatment initiation, particularly in rural areas where patients must travel long distances to access laboratory services.
Molecular diagnostic tools like the Pluslife Mini Dock enable rapid, accurate detection of TB bacteria and drug resistance patterns within hours, compared to traditional culture methods that can take weeks. Early and accurate diagnosis is critical for effective TB control, as undiagnosed patients continue transmitting the disease while their conditions deteriorate.
Dr Mya Ngon, Cluster Lead for Disease Prevention and Control at WHO Nigeria, speaking at the same briefing ahead of the 2026 World TB Day, acknowledged progress in Nigeria’s TB response but highlighted significant gaps in reaching underserved populations most vulnerable to infection and poor treatment outcomes.
Emphasizing the 2026 World TB Day theme, “Yes, We Can End TB! Led by Countries and Powered by People,” Ngon stated that ending the TB epidemic was achievable through sustained investment, accountability, and collective action.
“We must stand together with millions affected by TB and remember those who have lost their lives. Ending TB is possible with strong leadership and active community involvement,” she stated.
Ngon stressed that TB transcends purely medical concerns, representing a significant socio-economic challenge that imposes substantial financial burdens on patients and households, often hindering timely diagnosis and treatment completion.
“TB is not only a health issue but also a socio-economic concern, with financial burdens on patients and households hindering timely diagnosis and treatment,” she said, calling for financial risk protection measures and stronger domestic resource mobilisation to ensure programme sustainability.
The WHO official warned that Nigeria could not continue relying predominantly on external funding, particularly as support from the Global Fund might decline in future funding cycles, making domestic financing mechanisms essential for long-term programme viability.
“Nigeria is already preparing proposals for the next funding round while strengthening internal financing mechanisms to ensure sustainable TB programmes,” she stated.
The shift toward domestic financing reflects broader changes in global health funding architecture, as traditional donor countries reassess their international aid commitments amid domestic fiscal pressures and competing priorities. The United States, historically the largest contributor to global health initiatives, has signaled funding reductions across multiple disease programmes, forcing recipient countries to develop more self-reliant financing strategies.
Nigeria’s $200 million commitment, announced last year in response to anticipated donor withdrawals, represents a significant policy shift toward greater ownership of health programme financing. However, sustaining this level of domestic investment will require consistent political will, efficient budget execution, and protection of health allocations from competing fiscal demands.
The Global Fund to Fight AIDS, Tuberculosis and Malaria, established in 2002, has been a major financing mechanism for TB programmes in high-burden countries including Nigeria. The fund operates on three-year replenishment cycles, with donor countries pledging contributions based on their economic capacity and political priorities. Nigeria has historically received substantial allocations for TB, HIV, and malaria programmes, enabling expansion of diagnostic services, treatment availability, and prevention initiatives.
However, recent replenishment cycles have seen reduced contributions from some traditional donors, raising concerns about programme sustainability in recipient countries. This has prompted increased emphasis on domestic resource mobilization, particularly among middle-income countries with growing fiscal capacity.
Nigeria’s TB response faces multiple challenges beyond financing, including weak health infrastructure in rural areas, shortage of trained healthcare workers, poor disease surveillance systems, and stigma that prevents individuals from seeking timely care. Drug-resistant TB, which requires more expensive and longer treatment regimens, adds complexity to programme management and increases financial requirements.
The WHO continues providing technical guidance, policy development support, and global best practice recommendations to strengthen Nigeria’s TB response and improve patient outcomes, Ngon affirmed.
World TB Day, observed annually on March 24, commemorates the 1882 discovery of the TB bacterium by Dr Robert Koch, which opened the pathway for diagnosis and cure of the disease. The day serves to raise public awareness about the devastating health, social, and economic consequences of TB and to mobilise political and social commitment to accelerate efforts to end the epidemic.
The 2026 theme emphasizes country leadership and people-centered approaches, reflecting recognition that sustainable TB elimination requires domestic ownership, adequate financing, and active engagement of affected communities rather than dependence on external actors.
Nigeria’s allocation of N73.4 billion for TB drugs represents approximately 0.2 percent of the proposed 2026 federal budget, signaling modest but growing political commitment to addressing the disease burden through domestic resources.
The Federal Ministry of Health has not provided a detailed breakdown of how the N73.4 billion will be distributed across different drug categories, diagnostic commodities, or implementation timelines as of the time of this report.